2096 Panoramica delle azioni Simcere Pharmaceutical Group Limited si occupa di ricerca, sviluppo, produzione e vendita di prodotti farmaceutici per distributori e catene di farmacie e altri produttori farmaceutici in Cina. Maggiori dettagli
Premi Analisi del rischio Non sono stati rilevati rischi per 2096 dai nostri controlli di rischio.
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Simcere Pharmaceutical Group Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Simcere Pharmaceutical Group Prezzi storici delle azioni Prezzo attuale dell'azione HK$6.79 Massimo di 52 settimane HK$7.70 Minimo di 52 settimane HK$4.94 Beta 0.43 Variazione di 1 mese -0.15% Variazione a 3 mesi -6.60% Variazione di 1 anno 19.12% Variazione a 3 anni -8.37% Variazione a 5 anni n/a Variazione dall'IPO -38.16%
Notizie e aggiornamenti recenti
Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for Sim0505 (CDH6 Antibody-Drug Conjugate) Issued by the National Medical Products Administration Jan 06
Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Sanbexin Sublingual Tablets in China by the National Medical Products Administration Dec 02
Simcere Pharmaceutical Group Limited Announces Inclusion of Three Innovative Drugs, Cosela, Enlituo and Sanbexin, in the New National Reimbursement Drug List Nov 28
Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable Nov 21
Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference Oct 30
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Sep 29 Vedi altri aggiornamenti
Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for Sim0505 (CDH6 Antibody-Drug Conjugate) Issued by the National Medical Products Administration Jan 06
Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Sanbexin Sublingual Tablets in China by the National Medical Products Administration Dec 02
Simcere Pharmaceutical Group Limited Announces Inclusion of Three Innovative Drugs, Cosela, Enlituo and Sanbexin, in the New National Reimbursement Drug List Nov 28
Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable Nov 21
Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference Oct 30
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Sep 29
Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration Sep 05
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Aug 24
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration Aug 22
Simcere Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024 Aug 09
Now 22% overvalued Aug 03
Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing Jul 29
Simcere Pharmaceutical Group Limited Announces New Drug Application of Quviviq (Daridorexant Hydrochloride Tablets) Has Been Accepted by the National Medical Products Administration Jul 17
Simcere Pharmaceutical Group Limited Announces Regular Approval of Xiannuoxin, an Anti-Sars-Cov-2 Innovative Drug Jul 11
Co-Founder recently sold HK$1.2m worth of stock Jun 28
Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China Jun 25 Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback for 260,976,161 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2024. Jun 20
Upcoming dividend of CN¥0.16 per share Jun 11
Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China Jun 01
Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong May 23
Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems May 01
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 26
Consensus revenue estimates fall by 14% Mar 22
Dividend of CN¥0.16 announced Mar 22 Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024
Consensus EPS estimates fall by 37% Mar 16
Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China Mar 16
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration Mar 13
Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500 Mar 12
Simcere Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 09
Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023 Feb 20
Consensus EPS estimates fall by 35% Feb 20
Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19 Jan 19
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets Jan 12
Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market Dec 29
Simcere Pharmaceutical Group Limited Announces Localization Application of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China Dec 27
Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug for SIM0501 (An Usp1 Small-Molecule Inhibitor) Issued by U.S. Food and Drug Administration Dec 04
Simcere Pharmaceutical Group Limited and Neurodawn Pharmaceutical Co., Ltd. Obtains Clinical Trial Approval Issued by the National Medical Products Administration Nov 30
Simcere Pharmaceutical Group Limited Announces Approval of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China Oct 31
Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for New Indication of Sim0237 for Injection (Anti-Pd-L1/IL-15 Bispecific Antibody) Issued by the National Medical Products Administration Oct 17
Co-Founder recently bought HK$1.2m worth of stock Aug 31
Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates Aug 28
Consensus revenue estimates fall by 22% Aug 28
First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022) Aug 22
Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023 Aug 10
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration Jul 28
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration Jul 23
Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023. Jul 01
Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023. Jun 30
Co-Founder recently sold HK$710k worth of stock Jun 30
New minor risk - Insider selling Jun 23
Co-Founder recently sold HK$2.3m worth of stock Jun 21
Simcere Pharmaceutical Group Limited Approves Final Cash Dividend for the Year Ended December 31, 2022, Payable on 12 July 2023 Jun 16
Co-Founder recently bought HK$1.5m worth of stock Jun 15
Upcoming dividend of CN¥0.16 per share at 2.3% yield Jun 12
Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%? Jun 03
Co-Founder recently sold HK$3.1m worth of stock Apr 30
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 19
Investor sentiment improves as stock rises 15% Apr 13
Consensus revenue estimates fall by 13% Apr 11
Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically Apr 06
Now 23% undervalued Feb 06
Simcere Pharmaceutical Group Limited Announces Conditional Approval for Marketing in China of Anti-Sars-Cov-2 Innovative Drug Xiannuoxin Tm Granted by the National Medical Products Administration Jan 30
Simcere Pharmaceutical Group Limited Announces Appointment Wang Xi as an Executive Director and the Appointment of Sung Ka Woon as an Independent Non-Executive Director Jan 19
Investor sentiment deteriorated over the past week Jan 19
Simcere Pharmaceutical Group Limited Announces Acceptance of New Drug Application of Anti-SARS-CoV-2 Innovative Drug Xiannuoxin (Simnotrelvir Tablets/Ritonavir Tablets (Co-Packaged)) by the National Medical Products Administration Jan 17
Now 24% undervalued Jan 17
Co-Founder recently bought HK$7.9m worth of stock Jan 11
Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096) Jan 10 Simcere Pharmaceutical Group Limited Appoints Mr. Tang Renhong as the Chairman of the Board of Directors and Chief Executive Officer of Simcere Zaiming Pharmaceutical Co., Ltd., with Effect from January 1, 2023
Simcere Pharmaceutical Group Limited Announces - the Clinical Trial Approval for SIM0348 Injection (Humanized TIGIT/PVRIG Bispecific Antibody) Issued by the National Medical Products Administration Dec 30
Now 20% undervalued Dec 30
Investor sentiment improved over the past week Dec 29
Simcere Pharmaceutical Group Announces Phase II/III Clinical Trial of Its 3Cl-Targeting anti-SARS-CoV-2 Drug Candidate Complete All Patients Enrollment Dec 21
Simcere Pharmaceutical Group Limited Announces A Phase II/III Clinical Study of Anti-Sars-COV-2 Drug Candidate XIANNUOXIN (SIM0417) Complete All Patients Enrollment Dec 19
Investor sentiment deteriorated over the past week Dec 06
Simcere Pharmaceutical Group Limited Announces A Multi-Center, Randomized, Double-Blind, Parallel and Placebo-Controlled Phase III Clinical Study Dec 03
Insufficient new directors Nov 16
Simcere Pharmaceutical Group Limited Announces Executive Changes Nov 10
Investor sentiment improved over the past week Nov 02
Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug Application Oct 28
Investor sentiment improved over the past week Oct 14
First half 2022 earnings released: EPS: CN¥0.024 (vs CN¥0.21 in 1H 2021) Oct 01
Consensus EPS estimates fall by 20% Sep 07
Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP Sep 07
Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP Sep 06
First half 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.21 in 1H 2021) Sep 01
Simcere Pharmaceutical Group Limited Announces Executive and Committee Changes Sep 01
Simcere Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 31, 2022 Aug 20
With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case Aug 16
Simcere Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022 Aug 02
Cosela, the World's First Comprehensive Myeloprotection Drug Against Chemotherapy Damage, Wins Approval in China Jul 19
Simcere Pharmaceutical Group Limited Announces Conditional Marketing of COSELA (Trilaciclib Hydrochloride for Injection) in China by the National Medical Products Administration Jul 14
Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18 Jun 27 Rendimenti per gli azionisti 2096 HK Pharmaceuticals HK Mercato 7D 2.3% 1.4% 1.9% 1Y 19.1% 0.8% 20.8%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 2096 ha superato il Hong Kong Pharmaceuticals che ha restituito 0.8 % nell'ultimo anno.
Rendimento vs Mercato: 2096 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 20.8 % nell'ultimo anno.
Volatilità dei prezzi Is 2096's price volatile compared to industry and market? 2096 volatility 2096 Average Weekly Movement 5.9% Pharmaceuticals Industry Average Movement 4.9% Market Average Movement 6.4% 10% most volatile stocks in HK Market 13.9% 10% least volatile stocks in HK Market 3.0%
Prezzo delle azioni stabile: 2096 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Hong Kong.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di 2096 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1995 6,412 Jinsheng Ren www.simcere.com
Simcere Pharmaceutical Group Limited si occupa di ricerca, sviluppo, produzione e vendita di prodotti farmaceutici per distributori e catene di farmacie e altri produttori farmaceutici in Cina. L'azienda si concentra su diverse aree terapeutiche, tra cui oncologia, sistema nervoso centrale, autoimmuni, antinfettivi, cardiovascolari e altre. I suoi prodotti principali includono Sanbexin, una soluzione iniettabile concentrata di edaravone e dexborneolo; Endostar, un'iniezione di endostatina umana ricombinante; ENWEIDA, un'iniezione di envafolimab; COSELA, un cloridrato di trilaciclib per iniezione; Iremod, una compressa di iguratimod; e XIANNUOXIN, una compressa di simnotrelvir/ritonavir.
Mostra di più Simcere Pharmaceutical Group Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Simcere Pharmaceutical Group con la sua capitalizzazione di mercato? 2096 statistiche fondamentali Capitalizzazione di mercato HK$16.89b Guadagni(TTM ) -HK$1.18b Ricavi(TTM ) HK$6.81b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 2096 Conto economico (TTM ) Ricavi CN¥6.34b Costo del fatturato CN¥1.45b Profitto lordo CN¥4.88b Altre spese CN¥5.99b Guadagni -CN¥1.10b
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.44 Margine lordo 77.05% Margine di profitto netto -17.39% Rapporto debito/patrimonio netto 14.5%
Come si è comportato 2096 nel lungo periodo?
Vedi performance storica e confronto Dividendi
2.5% Rendimento attuale del dividendo
-37% Rapporto di remunerazione
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/26 09:59 Prezzo dell'azione a fine giornata 2025/01/24 00:00 Guadagni 2024/06/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Simcere Pharmaceutical Group Limited è coperta da 16 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Sharon Shi BOCI Research Ltd. Shaojing Tong BofA Global Research Bo Yu China International Capital Corporation Limited
Mostra 13 altri analisti 
